Biotech CEO tells of biosimilars’ capacity to curb drug spendIn a Thursday interview, Dámaso Molero, CEO of biotech 3P Biopharmaceuticals, told financial Cinco Días about the firm’s origins, its goals and how biosimilars can reduce the country’s drug bill.
Onzeald presented as 'promising' for breast cancer with brain metastasesNektar Therapeutics’ Onzeald (etirinotecan pegol) was presented as a promising therapy for breast cancer with brain metastases in a Thursday story in daily La Razón. The CHMP rejected it in July because its benefit had not been sufficiently demonstrated. (APMHE 54018)
Allergan’s U.S. patent strategy backfiresShares of Allergan fell 5% on Monday after a U.S. court invalidated patents on the firm’s drug Restasis (cyclosporine), which Allergan had tried to protect by selling it to a Native American tribe, financial Cinco Días reported on Wednesday. (APMHE 55181)
Catalan conflict damages Spain’s bid for EMADuring the presentation of Barcelona’s bid to host EMA after Brexit the impact of the Catalan conflict on the candidacy was patent, daily El País reported on Thursday.
TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to our last stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.